76
|
Dréno B, Dupin N. [What future for dermatology in university hospitals?]. Ann Dermatol Venereol 2017; 145:157-158. [PMID: 29229191 DOI: 10.1016/j.annder.2017.11.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
77
|
Saint-Jean M, Corvec S, Nguyen JM, Le Moigne M, Boisrobert A, Khammari A, Dréno B. L’acné de la femme adulte n’est pas liée à un phylotype particulier de Propionibacterium acnes. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
78
|
Chasseuil E, Saint-Jean M, Catto-Smith H, Peuvrel L, Quereux G, Nguyen JM, Gaultier A, Varey E, Khammari A, Dréno B. Biomarqueurs prédictifs sanguins de bonne réponse au nivolumab dans le mélanome avancé : une cohorte rétrospective. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
79
|
Dagnelie MA, Corvec S, Saint-Jean M, Bourdès V, Nguyen JM, Khammari A, Dréno B. La sévérité de l’acné est associée à une perte de la diversité des souches de Propionibacterium acnes en peau acnéique. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.168] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
80
|
Quereux G, Bourdon M, Blanchin M, Tessier P, Campone M, Dravet F, Sebille V, Dréno B, Bonnaud-Antignac A. Évolution de la qualité de vie au cours du temps suite à un diagnostic d’un mélanome ou d’un cancer du sein : résultats comparatifs sur deux ans. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
81
|
Khammari A, Bourdès V, Blanchet-Réthoré S, Marty C, Piketty C, Dréno B. Évolution naturelle des nodules dans l’acné nodulaire sévère du dos : résultats d’une étude prospective de 4 semaines. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
82
|
Le Moigne M, Bulteau S, Bronnec MG, Gerardin M, Jonville-Bera AP, Fournier JP, Jolliet P, Dréno B, Vigneau C. Troubles psychiatriques, acné et rétinoïdes systémiques : comparaison des risques. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
83
|
Lesage C, Longvert C, Prey S, Maanaoui S, Dréno B, Machet L, Zehou O, Kramkimel N, Jeudy G, Skowron F, Aubin F, Visseaux L, Mansard S, Guillot B. Incidence et impact du traitement par anti-TNFα des colites sévères sous immunothérapie du mélanome : étude MECOLIT. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
84
|
Poli F, Claudel JP, Auffret N, Leccia MT, Dréno B. Cosmétiques et médicaments topiques dans l’acné : où est la frontière ? Ann Dermatol Venereol 2017; 144:768-775. [DOI: 10.1016/j.annder.2017.08.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2016] [Revised: 05/12/2017] [Accepted: 08/09/2017] [Indexed: 10/18/2022]
|
85
|
Muguet Guenot L, Vourc’h Jourdain M, Saint Jean M, Corvec S, Lemoigne M, Khammari A, Gaultier A, Dréno B. Microscopie confocale et acné de la femme adulte. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
86
|
Daguze J, Saint-Jean M, Quereux G, Peuvrel L, Muguet-Guenot L, Josselin N, Vergier B, Dréno B. Combinaison propranolol et cyclophosphamide dans l’angiosarcome : à propos de deux cas. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
87
|
Larkin J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey C, Lao C, Schadendorf D, Ferrucci P, Smylie M, Dummer R, Hill A, Haanen J, Maio M, McArthur G, Lebbé C, Dréno B, Walker D, Rollin L, Horak C, Hodi F, Wolchok J. Survie globale avec l’association de nivolumab (NIVO) et d’ipilimumab (IPI) dans un essai de phase III sur le mélanome avancé (CheckMate 067). Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
88
|
Quereux G, Herbreteau G, Knol AC, Vallee A, Khammari A, Theoleyre S, Saint-Jean M, Dréno B, Denis M. Prise en charge en urgence d’un mélanome métastatique explosif grâce à l’analyse de l’ADN circulant. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
89
|
Soenen A, Moureaux P, Pistorius V, Dréno B. Un cas de macrochéilite de Miescher traité efficacement par minocycline. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
90
|
Figueras Nart I, Cerio R, Dirschka T, Dréno B, Lear JT, Pellacani G, Peris K, Ruiz de Casas A. Defining the actinic keratosis field: a literature review and discussion. J Eur Acad Dermatol Venereol 2017; 32:544-563. [PMID: 29055153 DOI: 10.1111/jdv.14652] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Despite the chronic and increasingly prevalent nature of actinic keratosis (AK) and existing evidence supporting assessment of the entire cancerization field during clinical management, a standardized definition of the AK field to aid in the understanding and characterization of the disease is lacking. The objective of this review was to present and appraise the available evidence describing the AK cancerization field, with the aim of determining a precise definition of the AK field in terms of its molecular (including genetic and immunological), histological and clinical characteristics. Eight European dermatologists collaborated to conduct a review and expert appraisal of articles detailing the characteristics of the AK field. Articles published in English before August 2016 were identified using PubMed and independently selected for further assessment according to predefined preliminary inclusion and exclusion criteria. In addition, a retrospective audit of patients with AK was performed to define the AK field in clinical terms. A total of 32 review articles and 47 original research articles provided evidence of sun-induced molecular (including genetic and immunological) and histological skin changes in the sun-exposed area affected by AK. However, the available literature was deemed insufficient to inform a clinical definition of the AK field. During the retrospective audit, visible signs of sun damage in 40 patients with AK were assessed. Telangiectasia, atrophy and pigmentation disorders emerged as 'reliable or very reliable' indicators of AK field based on expert opinion, whereas 'sand paper' was deemed a 'moderately reliable' indicator. This literature review has revealed a significant gap of evidence to inform a clinical definition of the AK field. Therefore, the authors instead propose a clinical definition of field cancerization based on the identification of visible signs of sun damage that are reliable indicators of field cancerization based on expert opinion.
Collapse
|
91
|
Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Arenberger P, Fife K, Raimundo A, Dika E, Dimier N, Fittipaldo A, Xynos I, Hansson J. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. Eur J Cancer 2017; 86:334-348. [PMID: 29073584 DOI: 10.1016/j.ejca.2017.08.022] [Citation(s) in RCA: 185] [Impact Index Per Article: 26.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2017] [Revised: 07/04/2017] [Accepted: 08/28/2017] [Indexed: 01/27/2023]
Abstract
BACKGROUND The SafeTy Events in VIsmodEgib study (STEVIE, ClinicalTrials.gov, NCT01367665), assessed safety and efficacy of vismodegib-a first-in-class Hedgehog pathway inhibitor demonstrating clinical benefit in advanced basal cell carcinoma (BCC)-in a patient population representative of clinical practice. Primary analysis data are presented. PATIENTS AND METHODS Patients with locally advanced or metastatic BCC received oral vismodegib 150 mg/d until progressive disease, unacceptable toxicity, or withdrawal. Primary objective was safety. Efficacy variables were assessed as secondary end-points. RESULTS Evaluable adult patients (N = 1215, 1119 locally advanced; 96 metastatic BCC) from 36 countries were treated; 147 patients (12%) remained on study at time of reporting. Median (range) treatment duration was 8.6 (0-44) months. Most patients (98%) had ≥1 treatment-emergent adverse event (TEAE). The incidence of the most common TEAEs was consistent with reports in previous analyses. No association between creatine phosphokinase (CPK) abnormalities and muscle spasm was observed. Serious TEAEs occurred in 289 patients (23.8%). Exposure ≥12 months did not lead to increased incidence or severity of new TEAEs. The majority of the most common TEAEs ongoing at time of treatment discontinuation resolved by 12 months afterwards, regardless of Gorlin syndrome status. Response rates (investigator-assessed) in patients with histologically confirmed measurable baseline disease were 68.5% (95% confidence interval (CI) 65.7-71.3) in patients with locally advanced BCC and 36.9% (95% CI 26.6-48.1) in patients with metastatic BCC. CONCLUSIONS The primary analysis of STEVIE demonstrates that vismodegib is tolerable in typical patients in clinical practice; safety profile is consistent with that in previous reports. Long-term exposure was not associated with worsening severity/frequency of TEAEs. Investigator-assessed response rates showed high rate of tumour control. CLINICALTRIALS.GOV: NCT01367665.
Collapse
|
92
|
Le Moigne M, Fournier JP, Bulteau S, Grall-Bronnec M, Khammari A, Victorri-Vigneau C, Dréno B. Psychiatric disorders with systemic retinoids: a systematic review of case reports. Br J Dermatol 2017. [PMID: 28628192 DOI: 10.1111/bjd.15745] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
93
|
Bouloc A, Roo E, Imko‐Walczuk B, Moga A, Chadoutaud B, Dréno B. A skincare combined with combination of adapalene and benzoyl peroxide provides a significant adjunctive efficacy and local tolerance benefit in adult women with mild acne. J Eur Acad Dermatol Venereol 2017; 31:1727-1731. [PMID: 28573779 PMCID: PMC5697630 DOI: 10.1111/jdv.14379] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2017] [Accepted: 05/09/2017] [Indexed: 12/01/2022]
Abstract
INTRODUCTION Acne in adult women is an increasing reason for dermatological consultations. OBJECTIVE The aim of this study was to assess in adult women with mild acne the efficacy and tolerance of a daily adjunctive application of a skincare (Normaderm® , Laboratoires Vichy, France) to a fixed combination of adapalene/benzoyl peroxide daily or every other evening and a standard emollient. METHODS Subjects were randomized to receive the fixed combination applied either every evening or every other evening and a daily application of the standard emollient and the test care or a once daily application of the fixed combination and the standard emollient alone. Clinical evaluations at Day 0, Day 45 and Day 90 included the count of acne lesions, assessment of clinical improvement and local tolerance. The quantitative lipid profile of the stratum corneum of the forehead was also determined. RESULTS After 90 days of application, acne had improved in all 299 subjects with a statistically significant difference in favour of the test care regimens (P < 0.05). Moreover, skin quality, subject satisfaction, skin discomfort and sebum composition were in favour of these regimens. CONCLUSION In conclusion, the tested skincare combined with a fixed adapalene and benzoyl peroxide combination provides a significant adjunctive efficacy and local tolerance benefit in adult women with mild acne.
Collapse
|
94
|
Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun 2017; 8:592. [PMID: 28928380 PMCID: PMC5605517 DOI: 10.1038/s41467-017-00608-2] [Citation(s) in RCA: 151] [Impact Index Per Article: 21.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Accepted: 07/10/2017] [Indexed: 12/31/2022] Open
Abstract
Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune related adverse events and increasing use of ICB, predictors of response to CTLA-4 and/or PD-1 blockade represent unmet clinical needs. Using a systems biology-based approach to an assessment of 779 paired blood and tumor markers in 37 stage III MMel patients, we analyzed association between blood immune parameters and the functional immune reactivity of tumor-infiltrating cells after ex vivo exposure to ICB. Based on this assay, we retrospectively observed, in eight cohorts enrolling 190 MMel patients treated with ipilimumab, that PD-L1 expression on peripheral T cells was prognostic on overall and progression-free survival. Moreover, detectable CD137 on circulating CD8+ T cells was associated with the disease-free status of resected stage III MMel patients after adjuvant ipilimumab + nivolumab (but not nivolumab alone). These biomarkers should be validated in prospective trials in MMel.The clinical management of metastatic melanoma requires predictors of the response to checkpoint blockade. Here, the authors use immunological assays to identify potential prognostic/predictive biomarkers in circulating blood cells and in tumor-infiltrating lymphocytes from patients with resected stage III melanoma.
Collapse
|
95
|
Daguzé J, Saint-Jean M, Dréno B. Large nose angiosarcoma treated effectively with oral cyclophosphamide combined with propranolol. J Eur Acad Dermatol Venereol 2017; 32:e52-e54. [PMID: 28833588 DOI: 10.1111/jdv.14528] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
96
|
Lewis K, Larkin J, Ribas A, Flaherty K, McArthur G, Ascierto P, Dréno B, McKenna E, Zhu Q, Mun Y, Hauschild A. Impact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C+V): a pooled analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx377.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
97
|
Dréno B. What is new in the pathophysiology of acne, an overview. J Eur Acad Dermatol Venereol 2017; 31 Suppl 5:8-12. [DOI: 10.1111/jdv.14374] [Citation(s) in RCA: 154] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2017] [Accepted: 05/30/2017] [Indexed: 12/11/2022]
|
98
|
Quéreux G, Wylomanski S, Bouquin R, Saint-Jean M, Peuvrel L, Knol AC, Hanf M, Dréno B. Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas? J Eur Acad Dermatol Venereol 2017; 32:e39-e40. [PMID: 28750150 DOI: 10.1111/jdv.14486] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
99
|
Tan J, Thiboutot D, Gollnick H, Kang S, Layton A, Leyden J, Torres V, Guillemot J, Dréno B. Development of an atrophic acne scar risk assessment tool. J Eur Acad Dermatol Venereol 2017; 31:1547-1554. [DOI: 10.1111/jdv.14325] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Accepted: 04/04/2017] [Indexed: 12/26/2022]
|
100
|
Paugam C, Corvec S, Saint-Jean M, Le Moigne M, Khammari A, Boisrobert A, Nguyen J, Gaultier A, Dréno B. Propionibacterium acnesphylotypes and acne severity: an observational prospective study. J Eur Acad Dermatol Venereol 2017; 31:e398-e399. [DOI: 10.1111/jdv.14206] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|